Study to Evaluate the Pharmacokinetics of Selonsertib in Participants With Normal and Impaired Hepatic Function

Key Inclusion Criteria

All participants:

• Body mass index (BMI) from 18 to 40 kg/m^2, inclusive at study screening
• Creatinine clearance (CrCl) ≥ 60 mL/min (using the Cockcroft-Gault method) based on serum creatinine and actual body weight as measured at screening

Participants with impaired hepatic function:

• Aside from hepatic insufficiency, participants must be sufficiently healthy for study participation based upon screening evaluations.
• Must have diagnosis of chronic (> 6 months), stable hepatic impairment with no clinically significant change in hepatic status within the 3 months (90 days) prior to study drug administration (Day 1).
• Participants with severe hepatic impairment must have a score on the Child-Pugh-Turcotte scale of 10-15 at screening.
• Participants with moderate hepatic impairment must have a score on the Child-Pugh-Turcotte scale of 7-9 at screening.
• Participants with mild hepatic impairment must have a score on the Child-Pugh-Turcotte scale of 5-6 at screening.

Healthy participants (matched control):

• Must be in good health based upon screening evaluations.

Key Exclusion Criteria

All participants:

• Pregnant or lactating females
• Have received any investigational compound or device within 30 days prior to study dosing
• Current alcohol or substance abuse
• A positive test result for human immunodeficiency virus (HIV-1/2) antibody
• Have poor venous access that limits phlebotomy
• Have been treated with systemic steroids, anti-HIV agents, immunosuppressant therapies, or chemotherapeutic agents within 3 months prior to screening or expected to receive these agents during the study (eg, corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies) that would be contraindicated for other exclusion criteria.
• Significant serious skin disease, such as but not limited to rash, food allergy, eczema, psoriasis, or urticaria
• Significant drug sensitivity or drug allergy (such as anaphylaxis or hepatoxicity)
• Unstable cardiac disease, including history of myocardial infarction within 1 year of screening, recurrent episodes of ventricular tachycardia despite appropriate medical therapy, decompensated congestive heart failure, or dilated cardiomyopathy with left ventricular ejection fraction 1 time per month.
• Participants with hepatic impairment with co-morbid diseases not associated with hepatic impairment requiring medication(s) must be taking the medication(s) without a change in dose for > 3 months prior to screening.
• Changes in concomitant medications or dosage used to treat symptoms of hepatic impairment or associated co-morbid conditions that could lead to clinically significant changes in medical conditions during the course of the study that would affect the ability to interpret potential drug-drug interactions within 28 days prior to dosing.

Healthy participants (matched control):

• A positive test result for hepatitis C virus (HCV) antibody, hepatitis B surface antigen (HBsAg), or hepatitis B core antibody (anti-HBc)
• Positive test for drugs of abuse, including alcohol at screening or on Day -1/check-in.
• Have any serious or active medical or psychiatric illness (including depression) which, in the opinion of the investigator, would interfere with treatment, assessment, or compliance with the protocol.
• History of liver disease.
• Have taken any prescription medications or over-the-counter medications including herbal products within 28 days of commencing study drug dosing with the exception of vitamins, acetaminophen, ibuprofen, and hormonal contraceptive medications.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.